GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OSTO:MVIR) » Definitions » Net Cash per Share

Medivir AB (OSTO:MVIR) Net Cash per Share : kr0.27 (As of Sep. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Medivir AB Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Medivir AB's Net Cash per Share for the quarter that ended in Sep. 2024 was kr0.27.

The historical rank and industry rank for Medivir AB's Net Cash per Share or its related term are showing as below:

OSTO:MVIR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.69   Med: 3.18   Max: 250.25
Current: 9.67

During the past 13 years, the highest Price-to-Net-Cash Ratio of Medivir AB was 250.25. The lowest was 1.69. And the median was 3.18.

OSTO:MVIR's Price-to-Net-Cash is ranked worse than
75.06% of 838 companies
in the Biotechnology industry
Industry Median: 4.215 vs OSTO:MVIR: 9.67

Medivir AB Net Cash per Share Historical Data

The historical data trend for Medivir AB's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Net Cash per Share Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.57 2.45 1.12 0.95

Medivir AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.95 0.88 0.57 0.27

Competitive Comparison of Medivir AB's Net Cash per Share

For the Biotechnology subindustry, Medivir AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Medivir AB's Price-to-Net-Cash falls into.



Medivir AB Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Medivir AB's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(169.516-69.987-0)/104.495
=0.95

Medivir AB's Net Cash per Share for the quarter that ended in Sep. 2024 is calculated as

Net Cash per Share (Q: Sep. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(92.5-62.4-0)/112.168
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivir AB  (OSTO:MVIR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Medivir AB Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Medivir AB's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB Business Description

Traded in Other Exchanges
N/A
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB Headlines

No Headlines